Leverage a Fully-Integrated Immuno-Oncology Platform
OncoSec is seeking investment or partnership in the following areas:
TAVO in advanced melanoma and triple negative breast cancer
TAVO in additional solid tumor indications
Early-stage discovery programs for immune-oncology
Single-domain antibody and pipeline immune-oncology directed antibodies
Technology access program
OncoSec Lead Program: TAVO
Registration-directed study in advanced melanoma in combination with pembrolizumab in patients progressing on an approved checkpoint inhibitor (PISCES/KEYNOTE-695): Currently Enrolling
Planned clinical trial will evaluate the safety and efficacy of the combination in patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) who have previously failed at least one systemic chemotherapy or immunotherapy (OMS-141/KEYNOTE-890): In Progress
Potential to become the first marketed therapeutic to address the anti-PD-1 non-responder population
Fast track and orphan drug designations granted by the FDA
Data in melanoma and additional solid tumor indications show antigen-specific T-cell responses and conversion of “cold” to “hot”
OncoSec Pipeline Programs: A Modular System for Combinatorial Therapeutics
Multi-gene plasmid platform offers tunable expression of several genes from a single construct
Single-domain camelid antibody platform enables faster, less expensive antibody discovery with higher probability of success
Technology Access Program offers OncoSec technologies to partners for pre-clinical research
OncoSec Medical Inc. entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of OncoSec’s TAVO and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), a registered trademark of Merck Sharp & Dohme Corp. in a phase 2b clinical trial, referred to as PISCES/KEYNOTE-695.
OncoSec Medical Incorporated initiated a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park’s intravital microscopy (IVM) and OncoSec’s proprietary plasmid, TAVOPLUS, in combination with the recently announced APOLLO™ electroporation generator in preclinical studies.
OncoSec Medical Incorporated and Emerge Health, the leading Australian company providing full registration, reimbursement, sales, marketing and distribution services of therapeutic products in Australia and New Zealand, entered into a collaboration agreement commercializing OncoSec’s proprietary TAVO (enhanced IL-12 DNA-plasmid) and making it available under Australia’s Special Access Scheme (SAS).
OncoSec Medical Incorporated and Duke University School of Medicine, today announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary TAVOPLUS (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system. The research will be led by Herbert Kim Lyerly, M.D., George Barth Geller Professor, Professor of Immunology, Surgery and Pathology at Duke University School of Medicine.
OncoSec Medical Incorporated announced a triple combination clinical trial of OncoSec’s TAVO™, epacadostat, and KEYTRUDA® in patients with squamous cell carcinoma head and neck (SCCHN) cancer. This study, the “TRIFECTA” study, will be conducted by the UCSF Helen Diller Family Comprehensive Cancer Center.